Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155732 | 0.86 | EPHX2 (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL3993947 | 0.78 | CA1 (0.40) | — | |
| SCHEMBL3831238 | 0.77 | CYP2C19 (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL10002585 | 0.75 | PTGS1 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL468761 | 0.75 | KDM4E (0.56) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL24670606 | 0.75 | PTGS1 (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL8664606 | 0.75 | LMNA (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL43157 | 0.75 | ZDHHC20 (0.52) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2780184 | 0.73 | KDM4E (0.54) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL4809608 | 0.73 | ALDH1A1 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982668-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Pharmacyclics LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9162986-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS LLC | 2014-12-25 | — | — | US | disclosed |
| US-8778625-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130157298-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8299110-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors | PHARMACYCLICS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110269806-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYLICS, INC. A DELAWARE CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| US-7479502-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | PHARMACYCLICS LLC | 2006-09-14 | — | — | US | disclosed |
| US-5492802-A | SENSITIZING CYANINE DYE | EASTMAN KODAK COMPANY (US) | 1996-02-20 | — | — | US | disclosed |
| US-5418126-A | ELEMENT COMPRISING A LIGHT SENSITIVE EMULSION CONTAINING A SENSITIZING DYE | EASTMAN KODAK COMPANY (US) | 1995-05-23 | — | — | US | disclosed |
| US-5354651-A | Cyanine dyes as sensitizers; antisoilant | EASTMAN KODAK COMPANY (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0599383-A1 | Furan or pyrrole substituted dye compounds and silver halide photographic elements containing such dyes | EASTMAN KODAK COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0599384-A1 | Dye compounds and photographic elements containing such dyes | EASTMAN KODAK COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0599381-A1 | Dye compounds and silver halide photographic elements containing such dyes | EASTMAN KODAK COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0599382-A1 | hydroxyarylacyl dye compounds and silver halide photographic elements containing such dyes | EASTMAN KODAK COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| US-5316904-A | Cationic cyanine sensitizers in color photography | EASTMAN KODAK COMPANY (US) | 1994-05-31 | — | — | US | disclosed |
| EP-0595969-A1 | NUCLEATED HIGH CONTRAST PHOTOGRAPHIC ELEMENTS CONTAINING LOW-STAIN SENSITIZING DYES. | EASTMAN KODAK CO (US) | 1994-05-11 | — | — | EP | disclosed |
| US-5238779-A | Surface latent image forming high-chloride silver halide grains, hydrazide compound, amino compound and benzimidazolocarboxyanine dye | EASTMAN KODAK COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | F7, F9, F5 | PTGS1 492/4885PDE4A 4647/4885LMNA 1787/4885 |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | PTGS1 2349/4885PDE4A 3236/4885LMNA 478/4885 |
| US-20110269806-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | PTGS1 2349/4885PDE4A 3236/4885LMNA 478/4885 |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | F13B, HABP2, F7 | PTGS1 2349/4885PDE4A 3236/4885LMNA 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.